2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrials
2019
Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension
Garcia‐Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, Gallegos‐Orozco J, Reddy KR, Feyssa E, Chan JL, Yamashita M, Robinson JM, Spada AP, Hagerty DT, Bosch J. Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology 2019, 69: 717-728. PMID: 30063802, PMCID: PMC6587783, DOI: 10.1002/hep.30199.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCaspase 3FemaleHumansHypertension, PortalKeratin-18Liver CirrhosisMaleMiddle AgedPentanoic AcidsPortal PressureConceptsSevere portal hypertensionPortal hypertensionAlanine aminotransferaseCompensated cirrhosisEnd-stage liver disease (MELD) scoreAspartate aminotransferaseAST/alanine aminotransferaseChild class ALiver Disease scoreOpen-label studyNonserious adverse eventsPortal venous inflowAnti-inflammatory effectsHepatitis C virusSplanchnic vasodilationAdverse eventsHVPG measurementIntrahepatic inflammationPortal pressureBlood pressureCirrhosis etiologyMedian ageNonalcoholic steatohepatitisVenous inflowSignificant changes
2017
Validating, deconstructing and refining Baveno criteria for ruling out high‐risk varices in patients with compensated cirrhosis
Jangouk P, Turco L, De Oliveira A, Schepis F, Villa E, Garcia‐Tsao G. Validating, deconstructing and refining Baveno criteria for ruling out high‐risk varices in patients with compensated cirrhosis. Liver International 2017, 37: 1177-1183. PMID: 28160373, PMCID: PMC5511584, DOI: 10.1111/liv.13379.Peer-Reviewed Original ResearchConceptsHigh-risk varicesNegative predictive valueBaveno VI criteriaLiver stiffnessBaveno criteriaPredictive valueItalian cohortPlatelet countNon-invasive criteriaCohort of patientsNumber of endoscopiesUnnecessary endoscopiesCompensated cirrhosisPrimary prophylaxisRetrospective studyUS cohortVariceal screeningTransient elastographyVaricesHigh riskLow prevalenceCirrhosisPatientsEndoscopyClinical diagnosis
2012
The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis
Bari K, Miñano C, Shea M, Inayat IB, Hashem HJ, Gilles H, Heuman D, Garcia–Tsao G. The Combination of Octreotide and Midodrine Is Not Superior to Albumin in Preventing Recurrence of Ascites After Large-Volume Paracentesis. Clinical Gastroenterology And Hepatology 2012, 10: 1169-1175. PMID: 22801062, PMCID: PMC3678262, DOI: 10.1016/j.cgh.2012.06.027.Peer-Reviewed Original ResearchConceptsPostparacentesis circulatory dysfunctionRecurrence of ascitesVasoconstrictor groupAlbumin groupRefractory ascitesAscites recurrenceCombination of midodrineCombination of octreotidePlacebo-controlled trialLarge-volume paracentesisEffective blood volumeTreatment of choiceSingle intravenous doseOral midodrinePreventing RecurrenceRenal failureCirculatory dysfunctionMedian timeSerum levelsIntravenous doseIntramuscular injectionIntravenous administrationAscitesMidodrineBlood volume
2009
Use of Over-the-Counter Analgesics Is Not Associated With Acute Decompensation in Patients With Cirrhosis
Khalid SK, Lane J, Navarro V, Garcia–Tsao G. Use of Over-the-Counter Analgesics Is Not Associated With Acute Decompensation in Patients With Cirrhosis. Clinical Gastroenterology And Hepatology 2009, 7: 994-999. PMID: 19394441, PMCID: PMC3777825, DOI: 10.1016/j.cgh.2009.04.015.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdultAgedAged, 80 and overAlcohol DrinkingAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalCase-Control StudiesContraindicationsFemaleHospitalizationHumansLiverLiver CirrhosisMaleMiddle AgedNonprescription DrugsPainProspective StudiesSurveys and QuestionnairesYoung AdultConceptsNonsteroidal anti-inflammatory drugsAcute hepatic decompensationAnti-inflammatory drugsCirrhotic patientsAlcohol ingestionCounter analgesicsHepatic decompensationAlcoholic cirrhosisNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useDecompensation of cirrhosisConsecutive cirrhotic patientsTertiary care hospitalEffect of analgesicsCase-control studyRecent alcohol ingestionRecent alcohol useAcetaminophen useLiver clinicNoncirrhotic controlsNoncirrhotic patientsAcute decompensationFurther decompensationCare hospitalConsecutive patients
2005
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†. Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.Peer-Reviewed Original ResearchConceptsCompletion of therapyVirological responsePatient demographicsSubstance useAntiviral therapyMental illnessHepatitis C virus infectionLiver disease characteristicsC virus infectionNIH Consensus ConferenceType of therapyLiver clinicSVR ratesHCV RNAPositive patientsRelative contraindicationTherapy completionTreatment patternsLiver diseaseTreatment eligibilityDisease characteristicsPatient populationPoor adherenceVirus infectionConsensus conference
1995
Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study
Buonamico P, Sabbá C, Garcia‐Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen J, Lerner E, Taylor K, Albano O, Groszmann R. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double‐blind randomized echo‐doppler study. Hepatology 1995, 21: 134-139. PMID: 7806146, DOI: 10.1002/hep.1840210123.Peer-Reviewed Original ResearchConceptsPortal vein cross-sectional areaPostprandial splanchnic hyperemiaSuperior mesenteric arterySMA-VCirrhotic patientsSplanchnic hyperemiaSplanchnic hemodynamicsPlacebo administrationMeal ingestionPV-VFasted stateVein cross-sectional areaEcho-Doppler studyEffect of octreotideCrossover studyMesenteric arteryPulsatility indexLiquid mealPatientsSeparate daysCross-sectional areaSignificant decreaseIngestionHyperemiaSignificant increase
1990
Usefulness of the histologic and microbiologic study of liver biopsy in the diagnosis of fever of unknown origin.
Páez-Rodríguez O, García-Tsao G, Sifuentes J. Usefulness of the histologic and microbiologic study of liver biopsy in the diagnosis of fever of unknown origin. Revista De Gastroenterología De México 1990, 55: 1-6. PMID: 2291060.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiopsyFemaleFever of Unknown OriginHumansLiverMaleMiddle AgedRetrospective Studies
1989
Hepatic fibropolycystic disease in Mexico. Study of 82 cases.
Torres-Barrera G, García-Tsao G, Quiroz F, Ferrari. Hepatic fibropolycystic disease in Mexico. Study of 82 cases. Revista De Investigación Clínica 1989, 41: 45-52. PMID: 2727432.Peer-Reviewed Original ResearchConceptsCongenital hepatic fibrosisFibropolycystic diseaseLiver function testsPolycystic liver diseaseHepatic fibrosisCholedochal cystCaroli's diseaseLiver diseaseFunction testsMean agePolycystic kidneysInstituto Nacional de la NutriciónRenal insufficiencyVariceal hemorrhageSalvador ZubiránPolycystic diseaseIsolated diseaseIndividual patientsLarge seriesFibrosisCholangitisDiseasePatientsCystsKidney